Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema

Hassall, Mark; Andrew, Nicholas H

doi:10.1136/bcr-2015-212733

Cited by 14 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taxane-induced ME often needs withdrawal of treatment as topical dorzolamide has little effectiveness and anti-VEGF agents do not seem to have better results 164. ME in this condition is probably related to aquaporin interaction rather than inflammatory reactions 165.…”

Section: Therapeutic Managementmentioning

confidence: 99%

<p>Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges</p>

Massa

Pipis

Adewoyin

et al. 2019

OPTH

View full text Add to dashboard Cite

Macular edema (ME) is the most common sight-threatening complication in uveitis. The diagnostic and therapeutic management of the uveitic macular edema (UME) might be challenging due to the complex diagnostic workup and the difficulties physicians face to find the underlying cause, and due to its usually recurrent nature and the fact that it can be refractory to conventional treatment. Some of the mild cases can be treated with topical steroids, which can be combined with non-steroid anti-inflammatory drugs. However, immunomodulators such as methotrexate, tacrolimus, azathioprine, cyclosporine and mycophenolate mofetil together with anti-tumor necrosis factor-α (anti-TNF alpha) monoclonal antibodies such as adalimumab and infliximab, may be required to control the inflammation and the associated ME in refractory cases, or when an underlying disease is present. This review of the literature will focus mostly on the non-infectious UME.

show abstract

Section: Therapeutic Managementmentioning

confidence: 99%

<p>Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges</p>

Massa

Pipis

Adewoyin

et al. 2019

OPTH

View full text Add to dashboard Cite

show abstract

“…Topical administration of bevacizumab to the macula is reportedly an effective treatment for diabetic macular edema; however, there are no reports of its effect for systemic administration [6]. In addition, diabetic macular edema is characterized by vascular leakage, as measured by fluorescein angiography, owing to angiogenesis-related disorders, whereas macular edema caused by paclitaxel is characterized by no leakage.…”

Section: Discussionmentioning

confidence: 99%

“…Regarding paclitaxel-induced macular edema, treatment with oral dorzolamide (carbonic anhydrase inhibitor) is reportedly more effective than systemic bevacizumab treatment [6][7][8]. Although a detailed mechanism has not been elucidated, diabetic and drug-induced macular edema may exhibit varying pathogeneses and treatment modalities [9][10][11][12][13].…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy-induced cystoid macular edema in ovarian cancer

2020

EJGO

View full text Add to dashboard Cite

Chemotherapy for malignant tumors causes various adverse events that require treatment. Ovarian cancer treatment employs several drugs, including paclitaxel, carboplatin, and bevacizumab. Here the authors report a rare case of cystoid macular edema induced by treatment with paclitaxel and bevacizumab for recurrent ovarian cancer, which significantly reduces patients' quality of life. Case Report The present patient was a 63-year-old female. Primary debulking surgery was performed two years previously, and she was diagnosed with ovarian clear cell carcinoma pT2cN1M0, FIGO Stage 3A1 [2] (complete surgery). Six courses of first-line chemotherapy with paclitaxel and carboplatin were postoperatively administered without any severe adverse events. Two recurrent lesions of the peritoneum were observed seven months after the first course of treatment; the patient was again treated with paclitaxel and carboplatin. However, the lesions progressed during the six additional courses of treatment; hence, the recurrence was re-diagnosed with platinum resistant. Weekly paclitaxel and tri-weekly bevacizumab; paclitaxel-bevacizumab treatment was initiated. For the first three weeks, the patient was treated as an inpatient, whereas from the second course onwards, the patient was treated as an outpatient. Exertional dyspnea, eyelid edema, lower thigh edema, and visual abnormality began to appear during the second course of the treatment. Cardiac function was assessed via ultrasound examination for those symptoms, and mildly reduced ejection fraction of the left ventricular (58%) was observed. Up to six courses of chemotherapy were administered with strict follow-up. No change in blood pressure was observed, and cardiac function improved, as revealed by the increase in the ejection fraction (67%). However, her visual abnormality did not improve; the authors consulted an ophthalmologist, and she was diagnosed with cystoid macular edema based on the results of optical coherence tomography and angiography (Figure 1). The recurrent lesion was stable for 21 weeks, during which seven

show abstract

“…DTX is also known to cause cystoid macular edema. [21][22][23] There have been many reports of cystoid macular edema with PTX, [31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48] a taxane similar to DTX. The mechanism is believed to involve toxicity to Mu¨ller cells with subsequent intracellular fluid accumulation and subclinical leakage of extracellular fluid.…”

Section: Discussionmentioning

confidence: 99%

Current status of eye disorders caused by docetaxel administration every 3 weeks: A case-control study in Japanese patients

Noguchi

Kawashima²,

Maruyama³

et al. 2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Purpose Docetaxel is known to cause eye disorders. In this study, current status of eye disorders caused by docetaxel administration every 3 weeks in Japanese patients was examined. Methods This case-control study targeted patients who were newly administered docetaxel at the Kyoto Okamoto Memorial Hospital between 1 July 2015 and 30 June 2018. Eye disorder occurrence was defined as an event in which the pharmacist confirmed the symptoms in a patient interview and the ophthalmologist diagnosed the disorder. Results Of the 89 subjects, 7 (7.9%) had eye disorders. The symptoms were watering eyes (7.9%), a stye and eye discharge (2.2% each), corneal and conjunctival disorder, visual acuity reduction, and blepharedema (1.1% each). Four patients who presented with watering eyes, eye discharge, or corneal and conjunctival disorder showed improvement with the use of eye drops such as artificial tears. Two patients who presented with a stye showed improvement with the use of oral cefcapene. One patient with mild symptoms showed spontaneous improvement. However, one patient had irreversible visual acuity reduction. The multivariate logistic regression analysis revealed that a cumulative docetaxel dose of ≥300 mg/m2 (odds ratio: 15.50, 95% confidence interval: 1.37–175.00, p = 0.027) and concomitant cyclophosphamide use (odds ratio: 13.20, 95% confidence interval: 1.13–153.00, p = 0.039) were significant risk factors associated with eye disorders. Conclusion In conclusion, it was determined that docetaxel-related eye disorders might be influenced by the cumulative dose of docetaxel and concomitant cyclophosphamide use. In addition, relatively mild symptoms improved with medication.

show abstract

Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema

Cited by 14 publications

References 21 publications

<p>Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges</p>

<p>Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges</p>

Chemotherapy-induced cystoid macular edema in ovarian cancer

Current status of eye disorders caused by docetaxel administration every 3 weeks: A case-control study in Japanese patients

Contact Info

Product

Resources

About